A Phase 2, Double-blind, Randomized, Placebo-controlled Cross-over Study of Nelotanserin Versus Placebo in Lewy Body Dementia (LBD) Subjects Experiencing Visual Hallucinations (VH)

Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled Cross-over Study of Nelotanserin Versus Placebo in Lewy Body Dementia (LBD) Subjects Experiencing Visual Hallucinations (VH)

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Nelotanserin (Primary)
  • Indications Dementia; Lewy body disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Axovant Sciences
  • Most Recent Events

    • 08 Jan 2018 Results presented in an Axovant Sciences media release.
    • 08 Jan 2018 Results (corrected) presented in an Axovant Sciences media release.
    • 12 Dec 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top